| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$19.0M | ROE | −92.49% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $10.9M | Trading Days | 1247 |
| 52W High | 2.73 |
| 52W Low | 1.10 |
| % Off High | −59.34% |
| YTD | −52.56% | 1Y | −52.77% |
| 3Y | −97.16% | Since incept. (ann.) | −67.54% |
| Ann. Volatility (1Y) | 81.90% | Ann. Volatility (3Y) | 112.95% |
| Sharpe (1Y) | −0.54 | Sharpe (3Y) | −0.52 |
| Max Drawdown (1Y) | −57.14% | Max Drawdown (3Y) | −98.43% |
| Beta (3Y, vs SPY) | 1.00 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CVM | CEL SCI CORP | $10.2M | — |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $9.9M | — |
| INTS | INTENSITY THERAPEUTICS, INC. | $12.3M | — |
| PASG | Passage BIO, Inc. | $14.7M | — |
| ZIVO | Zivo Bioscience, Inc. | $15.6M | — |
| JSPR | Jasper Therapeutics, Inc. | $17.7M | — |
| PLUR | Pluri Inc. | $18.1M | — |
| PMCB | PharmaCyte Biotech, Inc. | $6.3M | 0.2 |
| TVGN | Tevogen Bio Holdings Inc. | $23.4M | — |
| GRML | Greenland Mines Ltd | $24.1M | — |
| LIMN | Liminatus Pharma, Inc. | $4.7M |
| APTOF | Aptose Biosciences Inc. | $4.3M | — |
